Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document

Abstract

In veterinary medical oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging to critically compare outcome measures across various treatment protocols. The Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here is based on the recommendations of a subcommittee of American College of Veterinary Internal Medicine (ACVIM) board-certified veterinary oncologists. This consensus paper has used the human response evaluation criteria in solid tumours (RECIST v1.1) as a framework to establish standard procedures for response assessment in canine solid tumours that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in veterinary oncology. It is hoped that this new canine RECIST (cRECIST v1.0) will be adopted within the veterinary oncology community and thereby facilitate the comparison of current and future treatment protocols used for companion animals with cancer.

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

“…Data collected included breed, weight, clinical signs at diagnosis and duration of clinical signs, findings of thoracic and abdominal imaging, histopathology results, blood pressure, results of fundic examinations, urine metanephrine/normetanephrine levels if available, evidence of cardiac arrhythmias, therapy prior to the start of toceranib, reason for toceranib use (inoperable measurable disease, microscopic disease, treatment of recurrent disease, metastatic disease, or maintenance after completion of other therapy), toceranib dose and dose schedule, duration of toceranib treatment, best response to treatment using previously defined criteria [28], side effects induced by toceranib using the veterinary cooperative oncology group-defined criteria [29], concurrent chemotherapy and supportive medications, concurrent diseases, and patient outcome.…”

The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

“…Partial response (PR) was defi ned as >30% reduction of the longest diameter of the target lesion. Progressive disease (PD) was defi ned as for >20% increase in the size of the longest target lesion, and stable disease was defi ned by the absence of criteria for either a response or progression [26].…”

Evaluation of an Accelerated Chemoradiotherapy Protocol for Oropharyngeal Squamous Cell Carcinoma in 5 Cats and 3 Dogs

“…All dogs had achieved a complete response by 6 to10-weeks after completion of therapy. 53 The most significant acute toxicity occurred in the mucosa (soft tissue reactions and local swellings) and could be assessed as grade 3 in all dogs but resolved quickly with a course of antibiotics (amoxicillin clavulanic acid i and metronidazole j ) and non-steroidal, anti-inflammatory drugs (carprofen l or meloxicam k ). The loss of mucosal integrity associated with bone exposure became evident after 4-days of radiotherapy due to the early tumor response in the dog with maxillary SCC and healed by second intention by 2-months following completion of radiation treatment (Fig.…”